CRL Charles River Laboratories

Q2 2025 10-Q

Filed: Aug 6, 2025Period ending Jun 28, 2025

Industrials

Services-Commercial Physical & Biological ResearchSEC EDGAR

Charles River Laboratories (CRL) 10-Q quarterly report for Q2 2025, filed with SEC EDGAR on Aug 6, 2025 for the fiscal period ending Jun 28, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q2 2025 10-Q

Risk Factors

• New trade tariffs risk triggered by April 2025 U.S. and other countries’ tariff delays but key tariffs on Vietnam, Mauritius, China remain affecting costs and supply chain
• Material regulatory risk updated with April 2025 FDA plans to reduce animal testing using NAMs; potential adverse impact on services and revenues highlighted

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$1.0B

Net Income

$52M

Net Margin

5.1%

Source: XBRL data from Charles River Laboratories Q2 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Charles River Laboratories Quarterly Reports

Q3 2025 10-Q

Q1 2025 10-Q

Get deeper insights on Charles River Laboratories

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.